DGAP-News

aap Implantate AG: First-time shareholder participation in the form of a share buyback following the sale of aap Biomaterials GmbH in financial year 2016 - Seite 2

"We are delighted to be able for the first time since aap went public in 1999 to give something back to our shareholders in the form of a share buyback programme," said Bruke Seyoum Alemu, Chairman of the Management Board (CEO) at aap. "We are also convinced that in offering our shareholders a price that is significantly above the average price over the past 12 months we are making a fair and attractive offer."

The acceptance period starts on Tuesday, 20 June 2017, 00.00 hours (CEST) and ends on Monday, 10 July 2017, 24.00 hours (CEST). The offer document will be published before the start of the acceptance period on the corporate website of the company (www.aap.de) in the section "Investors / Share Buyback" as well as in the Federal Gazette under www.bundesanzeiger.de.

After the successful completion of its transformation into a focussed trauma company aap will invest the major part of the proceeds from the sale of aap Biomaterials GmbH in further growth and the acceleration of its innovations such as the silver coating technology. The Management Board and Supervisory Board continue to consequently pursue the overarching target to unlock the inherent value of aap's innovative product and technology base and thereby creating sustainable value for the company's shareholders.

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.